Matching articles for "Menactra"
Issue 1726 · April 14, 2025 Free
Penmenvy — A Second Pentavalent Meningococcal Vaccine

The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old.…

Med Lett Drugs Ther. 2025 Apr 14; 67(1726):57-9 doi:10.58347/tml.2025.1726a
The FDA has licensed the pentavalent vaccine Penmenvy (GSK) for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penmenvy is the second pentavalent meningococcal vaccine to become available in the US; Penbraya was licensed in 2023.
Issue 1698 · March 18, 2024
Penbraya: A Pentavalent Meningococcal Vaccine

The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or…

Med Lett Drugs Ther. 2024 Mar 18; 66(1698):43-5 doi:10.58347/tml.2024.1698b
The FDA has licensed Penbraya (Pfizer), a pentavalent polysaccharide conjugate meningococcal vaccine, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, B, C, W, or Y (MenABCWY) in persons 10-25 years old. Penbraya is the only meningococcal vaccine that contains all five of these serogroups. Two quadrivalent polysaccharide conjugate meningococcal vaccines containing serogroups A, C, W, and Y (MenACWY; Menveo , MenQuadfi ) and two meningococcal serogroup B vaccines (MenB; Bexsero , Trumenba ) are available in the US (see Table 2).
Issue 1624 · May 17, 2021
MenQuadfi - A New Meningococcal (A, C, W, and Y) Vaccine

The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by…

Med Lett Drugs Ther. 2021 May 17; 63(1624):78-80
The FDA has licensed MenQuadfi (Sanofi Pasteur), a quadrivalent polysaccharide conjugate vaccine that uses tetanus toxoid as a protein carrier, for prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y (MenACWY) in persons ≥2 years old.
Issue 1612 · November 30, 2020 Free
In Brief: New Meningococcal Serogroup B Vaccination Recommendations

The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in…

Med Lett Drugs Ther. 2020 Nov 30; 62(1612):191-2
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
Issue 1560 · November 19, 2018 Free
Vaccines for Travelers

Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific…

Med Lett Drugs Ther. 2018 Nov 19; 60(1560):185-92
Persons planning to travel outside the US should be up to date on routine vaccines and, depending on their destination, duration of travel, and planned activities, may also receive certain travel-specific vaccines. Tickborne encephalitis and dengue vaccines, which are not available in the US, are reviewed in a separate article available online. Detailed advice for travel to specific destinations is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for administration of vaccines as part of routine adult immunization are discussed in a separate issue.
Issue 1560 · November 19, 2018 Free
Tickborne Encephalitis and Dengue Vaccines (online only)

No vaccines against tickborne encephalitis (TBE) or dengue are available in the US, but vaccines have been licensed in some other countries.

Med Lett Drugs Ther. 2018 Nov 19; 60(1560):e195
No vaccines against tickborne encephalitis (TBE) or dengue are available in the US, but vaccines have been licensed in some other countries.
Issue 1546 · May 7, 2018
Expanded Table: Some Vaccines Recommended for Use in Adults (online only)

View the Expanded Table: Some Vaccines Recommended for Use in Adults

Med Lett Drugs Ther. 2018 May 7; 60(1546):e82-5
View the Expanded Table: Some Vaccines Recommended for Use in Adults
Issue 1546 · May 7, 2018
Adult Immunization

The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with…

Med Lett Drugs Ther. 2018 May 7; 60(1546):73-82
The US Advisory Committee on Immunization Practices (ACIP) recommends routine use of the following vaccines in adults residing in the US: influenza, tetanus/diphtheria alone (Td) and in combination with acellular pertussis (Tdap), measles/mumps/rubella (MMR), varicella (VAR), herpes zoster (RZV; ZVL), human papillomavirus (HPV), and pneumococcal conjugate (PCV13) and polysaccharide (PPSV23) vaccines. For adults with certain medical conditions or occupational, behavioral, or other risk factors, hepatitis A (HepA), hepatitis B (HepB), meningococcal (MenACWY; MenB), and Haemophilus influenzae type b (Hib) vaccines are also recommended. Recommendations for vaccination against seasonal influenza and vaccination of travelers are reviewed separately.
Issue 1519 · April 24, 2017 Free
In Brief: New Adult Immunization Recommendations

The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations. 1 The complete schedule is available on the CDC's…

Med Lett Drugs Ther. 2017 Apr 24; 59(1519):70
The 2017 adult immunization schedule approved by the CDC's Advisory Committee on Immunization Practices (ACIP) includes some new or revised recommendations. 1 The complete schedule is available on the CDC's website ( www.cdc.gov/vaccines/schedule ). New recommendations for use of influenza vaccine during the 2016-2017 season were included in a previous issue of The Medical Letter . 2 Updated recommendations for other vaccines are summarized below. Recommendations for routine use of vaccines in adults were reviewed in an earlier issue. 3 DK Kim et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66:136. Influenza vaccine for 2016-2017. Med Lett Drugs Ther 2016; 58:127. Adult immunization. Treat Guidel Med Lett 2014; 12:39. Gardasil 9 – a broader HPV vaccine. Med Lett Drugs Ther 2015; 57:47. Trumenba: a serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:5. Bexsero – a second serogroup B meningococcal vaccine. Med Lett Drugs Ther 2015; 57:158. Download complete U.S. English article
Issue 1459 · January 5, 2015
Trumenba: A Serogroup B Meningococcal Vaccine

The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.

Med Lett Drugs Ther. 2015 Jan 5; 57(1459):5-6
The FDA has approved Trumenba (Pfizer), a vaccine that protects against invasive meningococcal disease caused by Neisseria meningitidis serogroup B, for use in adolescents and young adults 10-25 years old.
Issue 1456 · November 24, 2014
Vaccines for Travelers

Patients planning to travel to other countries should be up to date on routine immunizations and, depending on their destination, duration of travel, and planned activities, may also need to receive certain…

Med Lett Drugs Ther. 2014 Nov 24; 56(1456):115-20
Patients planning to travel to other countries should be up to date on routine immunizations and, depending on their destination, duration of travel, and planned activities, may also need to receive certain travel-specific vaccines. Common travel vaccines are listed in Table 2. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines for routine adult immunization are discussed in a separate issue.
Issue 142 · June 1, 2014
Adult Immunization

Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization…

Treat Guidel Med Lett. 2014 Jun; 12(142):39-48
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately. Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various ages...
Issue 118 · June 1, 2012
Advice for Travelers

Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for…

Treat Guidel Med Lett. 2012 Jun; 10(118):45-56
Patients planning to travel to other countries often ask for information about appropriate vaccines and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention (CDC) at www.cdc.gov/travel. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 112 · December 1, 2011
Adult Immunizations

Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.

Treat Guidel Med Lett. 2011 Dec; 9(112):75-82
Vaccines recommended for routine use in US adults are reviewed here. Vaccines for travel have been reviewed separately.
Issue 1364 · May 16, 2011 Free
In Brief: A Booster Dose of Meningococcal Vaccine for Adolescents

Evidence of waning immunity by 5 years post-vaccination has led the US Advisory Committee on Immunization Practices (ACIP) to recommend, in addition to a primary dose of meningococcal conjugate vaccine at 11…

Med Lett Drugs Ther. 2011 May 16; 53(1364):37
Evidence of waning immunity by 5 years post-vaccination has led the US Advisory Committee on Immunization Practices (ACIP) to recommend, in addition to a primary dose of meningococcal conjugate vaccine at 11 or 12 years of age, a booster dose at age 16. Adolescents who receive a first dose of the vaccine at age 13-15 should receive a booster dose at 16-18 (before college). Those who receive their first dose at ≥16 years of age do not need a booster dose. Routine vaccination of healthy persons who are not at increased risk for exposure to Neisseria meningitidis is not recommended after age 21. 1 1. CDC. Updated recommendations for use of meningococcal conjugate vaccines — Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2011; 60:72. Download U.S. English
Issue 1343 · July 26, 2010
A New Conjugate Meningococcal Vaccine (Menveo)

The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.

Med Lett Drugs Ther. 2010 Jul 26; 52(1343):59-60
The FDA has approved Menveo (Novartis), a new quadrivalent conjugated polysaccharide vaccine, for protection against disease caused by Neisseria meningitidis in people 11-55 years old.
Issue 87 · November 1, 2009
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases…

Treat Guidel Med Lett. 2009 Nov; 7(87):83-94
Patients planning to travel to other countries often ask physicians for information about appropriate vaccines and prevention of diarrhea and malaria. Guidelines are also available from the Infectious Diseases Society of America (IDSA).
Issue 80 · April 1, 2009
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2009 Apr; 7(80):27-36
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.
Issue 1291 · July 28, 2008 Free
A Reminder: Meningococcal Vaccine

The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine ( Menactra – Sanofi Pasteur) to all persons 11 to 18…

Med Lett Drugs Ther. 2008 Jul 28; 50(1291):57
The U.S. Advisory Committee on Immunization Practices has recommended administration of the quadrivalent conjugated polysaccharide meningococcal vaccine ( Menactra – Sanofi Pasteur) to all persons 11 to 18 years old, particularly those entering high school and college freshmen living in dormitories. 1,2 The peak incidence of meningococcal disease, after early childhood, occurs in the 15-19 year-old age group. The conjugate vaccine is more immunogenic than the meningococcal capsular polysaccharide vaccine ( Menommune – Sanofi Pasteur). ADVERSE EFFECTS — The most common adverse reactions with the conjugate vaccine have been headache, fatigue and malaise, in addition to pain, redness and induration at the injection site. Guillain-Barré syndrome has occurred rarely. 3 CONCLUSION — Previously unvaccinated children starting high school or going away to college this fall should receive a single dose of meningococcal conjugate vaccine (Menactra) . 1. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices. Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR Morb Mortal Wkly Rep 2007; 56:794. 2. Menactra: a meningococcal conjugate vaccine. Med Lett Drugs Ther 2005; 47:29. 3. Centers for Disease Control and Prevention (CDC). Update: Guillain-Barre syndrome among recipients of Menactra meningococcal conjugate vaccine — United States, October 2005-February 2006. MMWR Morb Mortal Wkly Rep 2006; 55:364. Download: U.S. English
Issue 47 · July 1, 2006
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2006 Jul; 4(47):47-54
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Immunizations for travel were reviewed in a recent issue.
Issue 45 · May 1, 2006
Advice for Travelers

Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers…

Treat Guidel Med Lett. 2006 May; 4(45):25-34
Patients planning to travel to other countries often ask physicians for information about immunizations and prevention of diarrhea and malaria. More detailed advice for travelers is available from the Centers for Disease Control and Prevention at 877-FYI-TRIP (877-394-8747) or www.cdc.gov/travel .
Issue 1206 · April 11, 2005
Menactra: A Meningococcal Conjugate Vaccine

The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied…

Med Lett Drugs Ther. 2005 Apr 11; 47(1206):29-31
The FDA has approved a conjugated polysaccharide vaccine, Menactra (Sanofi-Pasteur), for protection against disease caused by Neisseria meningitidis in people 11-55 years old, and the manufacturer has applied for approval for use in children 2 to 10 years old. An unconjugated meningoccocal polysaccharide vaccine ( Menomune - Sanofi-Pasteur) has been licensed in the US since 1981.